Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion
- PMID: 12804502
- DOI: 10.1002/14651858.CD004172
Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion
Update in
-
Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion.Cochrane Database Syst Rev. 2011 Mar 16;(3):CD004172. doi: 10.1002/14651858.CD004172.pub2. Cochrane Database Syst Rev. 2011. PMID: 21412885 Free PMC article.
Abstract
Background: Concerns regarding the safety of transfused blood have generated considerable enthusiasm for the use of technologies intended to reduce the use of allogeneic blood (blood from an unrelated donor). Platelet-rich plasmapheresis (PRP) offers an alternative approach to blood conservation.
Objectives: To examine the evidence for the efficacy of PRP in reducing peri-operative allogeneic red blood cell (RBC) transfusion, and the evidence for any effect on clinical outcomes such as mortality and re-operation rates.
Search strategy: Studies were identified by: computer searches of MEDLINE, EMBASE, Current Contents, and the Cochrane Library (to June 2001). These searches were supplemented by checking the reference lists of published articles, reports, and reviews.
Selection criteria: Controlled parallel group trials in which adult patients, scheduled for non-urgent surgery, were randomised to PRP, or to a control group who did not receive the intervention.
Data collection and analysis: Main outcomes measured were: the number of patients receiving an allogeneic RBC transfusion, and the amount of RBC transfused. Trial quality was assessed using criteria proposed by Schulz et al. (Schulz 1995) and Jadad et al. (Jadad 1996).
Main results: Nineteen trials of PRP were identified that reported data for the number of patients exposed to allogeneic RBC transfusion. These trials evaluated a total of 1452 patients. The pooled relative risk (RR) of exposure to allogeneic blood transfusion in those patients randomised to PRP was 0.71 (95%CI: 0.56, 0.90), equating to a relative risk reduction (RRR) of 29%; the average absolute risk reduction (ARR) was 19% (RD = -0.19: 95%CI: -0.29, -0.09). On average, PRP did not significantly reduce the total volume of RBC transfused (weighted mean difference [WMD] = -0.69: 95%CI: -1.93, 0.56 units). Substantial statistical heterogeneity was observed (p < 0.001). Trials provided inadequate data regarding the impact of PRP on morbidity, mortality, and hospital length of stay. The majority of trials were small and of poor methodological quality.
Reviewer's conclusions: Although the results suggest that PRP is effective in reducing allogeneic RBC transfusion in adult patients undergoing elective surgery, there was considerable heterogeneity in treatment effects and the trials were of poor methodological quality. As the majority of trials were unblinded, transfusion practices may have been influenced by knowledge of the patient's allocation status, potentially exaggerating the true magnitude of the beneficial effect of PRP. The available studies provided inadequate data for firm conclusions to be drawn regarding the impact of PRP on clinically important endpoints.
Similar articles
-
Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion.Cochrane Database Syst Rev. 2011 Mar 16;(3):CD004172. doi: 10.1002/14651858.CD004172.pub2. Cochrane Database Syst Rev. 2011. PMID: 21412885 Free PMC article.
-
Cell salvage for minimising perioperative allogeneic blood transfusion.Cochrane Database Syst Rev. 2003;(4):CD001888. doi: 10.1002/14651858.CD001888. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001888. doi: 10.1002/14651858.CD001888.pub2. PMID: 14583940 Updated.
-
Desmopressin for minimising perioperative allogeneic blood transfusion.Cochrane Database Syst Rev. 2004;(1):CD001884. doi: 10.1002/14651858.CD001884.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2017 Jul 10;7:CD001884. doi: 10.1002/14651858.CD001884.pub3. PMID: 14973974 Free PMC article. Updated.
-
Fibrin sealant use for minimising peri-operative allogeneic blood transfusion.Cochrane Database Syst Rev. 2003;2003(2):CD004171. doi: 10.1002/14651858.CD004171. Cochrane Database Syst Rev. 2003. PMID: 12804501 Free PMC article.
-
Cell salvage for minimising perioperative allogeneic blood transfusion.Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001888. doi: 10.1002/14651858.CD001888.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2010 Mar 17;(3):CD001888. doi: 10.1002/14651858.CD001888.pub3. PMID: 17054147 Updated.
Cited by
-
Comparing acute normovolumic hemodilution with autologous platelet-rich plasma for blood preservation during aortic surgery : study protocol for a randomized controlled clinical trial.Trials. 2023 Nov 18;24(1):741. doi: 10.1186/s13063-023-07800-4. Trials. 2023. PMID: 37980486 Free PMC article.
-
Investigating the impact of trial retractions on the healthcare evidence ecosystem (VITALITY Study I): retrospective cohort study.BMJ. 2025 Apr 23;389:e082068. doi: 10.1136/bmj-2024-082068. BMJ. 2025. PMID: 40268307 Free PMC article.
-
Serum Levels of VWF, t-PA, TNF-α, and ICAM-1 in Patients Receiving Hemocoagulase Combined with Platelet-Rich Plasma during Total Hip Replacement.Genet Res (Camb). 2022 Jan 27;2022:2766215. doi: 10.1155/2022/2766215. eCollection 2022. Genet Res (Camb). 2022. PMID: 35136382 Free PMC article.
-
Intraoperative Autologous Blood Transfusion in Aortic Surgery.Aorta (Stamford). 2024 Dec;12(6):153-161. doi: 10.1055/s-0045-1809172. Epub 2025 May 20. Aorta (Stamford). 2024. PMID: 40393660 Free PMC article.
-
A penalization approach to random-effects meta-analysis.Stat Med. 2022 Feb 10;41(3):500-516. doi: 10.1002/sim.9261. Epub 2021 Nov 18. Stat Med. 2022. PMID: 34796539 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous